Telomir Pharmaceuticals Stock Soars 123.97% on Promising Cancer Drug Data

On July 18, 2025, Telomir's stock surged by 123.97% in pre-market trading, marking a significant milestone for the company.

Telomir Pharmaceuticals has recently unveiled encouraging preclinical results for its lead compound, Telomir-1. The findings, presented in a murine xenograft model using PC3 human prostate cancer cells, demonstrate Telomir-1's capability to reverse epigenetic silencing of the STAT1 gene by modulating DNA methylation in a dose-dependent manner. STAT1, a critical tumor suppressor and immune response regulator, is frequently silenced in advanced cancers. Oral administration of Telomir-1 for 21 days completely reversed STAT1 hypermethylation in tumor samples, an outcome not achieved by the Paclitaxel group and only partially by Rapamycin.

In addition to its effects on STAT1, Telomir-1 significantly reduced hypermethylation of TMS1, another essential tumor suppressor gene involved in apoptosis and immune response. While Paclitaxel and Rapamycin also influenced TMS1 methylation, Telomir-1 uniquely targeted both STAT1 and TMS1. TMS1 plays a pivotal role in inflammasome activation, which aids in immune detection and promotes tumor cell death. By decreasing TMS1 hypermethylation, Telomir-1 could potentially enhance the efficacy of chemotherapy and immunotherapy. Importantly, Telomir-1 did not alter telomere length in tumor tissue, ensuring its selective activity without promoting tumor progression. Telomir continues to advance preclinical trials across various conditions, aiming to determine its initial IND indication.